Review of PD-L1 x 4-1BB Bispecific Antibodies for Tumor-Mediated T-cell Activation

STUTTGART, Germany, July 29, 2024 — La Merie Publishing has introduced its latest analysis covering the development of bispecific antibodies that target PD-L1 and 4-1BB, focusing on the promising therapeutic potential of these innovative drug candidates.

The product, titled "PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review," provides comprehensive insights into the ongoing research and development of these bispecific antibodies. The review is available immediately upon purchase, with customers receiving detailed competitor and project history reports in PDF format, as well as database access.

4-1BB, also known as CD137, is a receptor found on the surface of T-cells that becomes prominent upon activation. It belongs to the TNF receptor superfamily and plays a key role in stimulating T-cell activity. When the receptor is activated by its natural ligand or by agonistic antibodies, it can significantly enhance T-cell response and increase the production of inflammatory cytokines. This mechanism has demonstrated significant anticancer efficacy in various mouse models. However, the development of 4-1BB agonists for clinical use has faced challenges, primarily due to liver toxicity that occurs when the target is activated outside of tumor tissues.

PD-L1, or Programmed death-ligand 1, is a 40kDa protein involved in the suppression of the immune system's adaptive response. By binding to the PD-1 checkpoint molecule, PD-L1 sends inhibitory signals that decrease the proliferation of antigen-specific T-cells in lymph nodes while also reducing apoptosis in regulatory T cells. PD-L1 is found on both hematopoietic and nonhematopoietic cells and is particularly overexpressed in various cancers, including lung cancer.

One of the most advanced strategies for targeting 4-1BB involves using bispecific antibodies or bispecific fusion proteins. These are engineered to concentrate in the tumor microenvironment, thereby enabling tumor-specific activation of 4-1BB. This approach minimizes the risk of liver toxicity by ensuring that the activation of 4-1BB occurs only in the presence of tumor cells. Typically, these bispecific proteins consist of one arm that recognizes a tumor-associated antigen (TAA) and another arm that acts as a 4-1BB agonist.

Currently, several PD-L1 x 4-1BB bispecific antibodies are undergoing preclinical and clinical trials. These antibodies are designed to trigger an antitumor response by conditionally activating 4-1BB on T cells and natural killer (NK) cells. This activation is strictly dependent on the simultaneous binding of the PD-L1 arm to its target, ensuring that the immune response is directed specifically at tumor cells.

For those interested, the "PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review" is available for purchase on La Merie Publishing's website. The company specializes in providing business information for the biotechnology and pharmaceutical industries, offering a range of reports that can be customized for corporate clients. These include pipeline analysis, drug profiles, and other competitive intelligence services.

La Merie Publishing remains a valuable resource for stakeholders in the biotech and pharma sectors, supporting informed decision-making with its meticulously prepared reports and analyses.